Assessment of metabolic risk factors for nephrolithiasis in patients with autosomal dominant polycystic kidney disease: a cross-sectional study.
Autosomal dominant
Hypocitraturia
Nephrolithiasis
Polycystic kidney disease
Journal
Clinical and experimental nephrology
ISSN: 1437-7799
Titre abrégé: Clin Exp Nephrol
Pays: Japan
ID NLM: 9709923
Informations de publication
Date de publication:
Nov 2023
Nov 2023
Historique:
received:
21
10
2022
accepted:
07
07
2023
medline:
23
10
2023
pubmed:
26
7
2023
entrez:
26
7
2023
Statut:
ppublish
Résumé
Nephrolithiasis is more common in autosomal dominant polycystic kidney disease (ADPKD) than in the normal population. We aimed to investigate the anatomical and metabolic factors that may be associated with nephrolithiasis in patients with ADPKD METHODS: In this cross-sectional study, a total of 180 participants were included. Eighty-five patients with ADPKD [42 patients with nephrolithiasis (PKD N +) and 43 without nephrolithiasis (PKD N -)] were recruited. Forty-seven nephrolithiasis patients without ADPKD (N) and 48 healthy controls (HC) were selected as control groups. 24-h urine collections were measured in all participants. 24-h urine citrate, calcium, urate, oxalate, magnesium and sodium, serum electrolytes, and eGFRs were compared. Total kidney volumes were not different between patients with PKD N + and PKD N -. Hypocitraturia was common in all patients with ADPKD (69.4%), and it was not different between PKD N + (76.2%) and PKD N- (62.8%). However, hypocitraturia was statistically higher in PKD N + and PKD N - than in N (38.3%) and HC (12.5%) (p<0.05). 24-h urine calcium, urate, and oxalate levels were similar between PKD N + and PKD N - CONCLUSIONS: Hypocitraturia was found to be significantly higher in patients with ADPKD than in healthy adults and other kidney stone patients.
Sections du résumé
BACKGROUND
BACKGROUND
Nephrolithiasis is more common in autosomal dominant polycystic kidney disease (ADPKD) than in the normal population. We aimed to investigate the anatomical and metabolic factors that may be associated with nephrolithiasis in patients with ADPKD METHODS: In this cross-sectional study, a total of 180 participants were included. Eighty-five patients with ADPKD [42 patients with nephrolithiasis (PKD N +) and 43 without nephrolithiasis (PKD N -)] were recruited. Forty-seven nephrolithiasis patients without ADPKD (N) and 48 healthy controls (HC) were selected as control groups. 24-h urine collections were measured in all participants. 24-h urine citrate, calcium, urate, oxalate, magnesium and sodium, serum electrolytes, and eGFRs were compared.
RESULTS
RESULTS
Total kidney volumes were not different between patients with PKD N + and PKD N -. Hypocitraturia was common in all patients with ADPKD (69.4%), and it was not different between PKD N + (76.2%) and PKD N- (62.8%). However, hypocitraturia was statistically higher in PKD N + and PKD N - than in N (38.3%) and HC (12.5%) (p<0.05). 24-h urine calcium, urate, and oxalate levels were similar between PKD N + and PKD N - CONCLUSIONS: Hypocitraturia was found to be significantly higher in patients with ADPKD than in healthy adults and other kidney stone patients.
Identifiants
pubmed: 37493903
doi: 10.1007/s10157-023-02378-2
pii: 10.1007/s10157-023-02378-2
doi:
Substances chimiques
Uric Acid
268B43MJ25
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
912-918Informations de copyright
© 2023. The Author(s), under exclusive licence to The Japanese Society of Nephrology.
Références
Torres VE, Harris PC. Autosomal dominant polycystic kidney disease. Nefrologia. 2003;23(Suppl 1):14–22.
pubmed: 12708359
Torres VE, Harris PC. Autosomal dominant polycystic kidney disease: the last 3 years. Kidney Int. 2009;76(2):149–68.
doi: 10.1038/ki.2009.128
pubmed: 19455193
pmcid: 2812475
Levine E, Grantham JJ. Calcified renal stones and cyst calcifications in autosomal dominant polycystic kidney disease: clinical and CT study in 84 patients. AJR Am J Roentgenol. 1992;159(1):77–81.
doi: 10.2214/ajr.159.1.1609726
pubmed: 1609726
Torres VE, Erickson SB, Smith LH, Wilson DM, Hattery RR, Segura JW. The association of nephrolithiasis and autosomal dominant polycystic kidney disease. Am J Kidney Dis. 1988;11(4):318–25.
doi: 10.1016/S0272-6386(88)80137-9
pubmed: 3354568
Amar AD, Das S, Egan RM. Management of urinary calculous disease in patients with renal cysts: review of 12 years of experience in 18 patients. J Urol. 1981;125(2):153–6.
doi: 10.1016/S0022-5347(17)54943-5
pubmed: 7206042
Torres VE, Wilson DM, Hattery RR, Segura JW. Renal stone disease in autosomal dominant polycystic kidney disease. Am J Kidney Dis. 1993;22(4):513–9.
doi: 10.1016/S0272-6386(12)80922-X
pubmed: 8213789
Grampsas SA, Chandhoke PS, Fan J, Glass MA, Townsend R, Johnson AM, Gabow P. Anatomic and metabolic risk factors for nephrolithiasis in patients with autosomal dominant polycystic kidney disease. Am J Kidney Dis. 2000;36(1):53–7.
doi: 10.1053/ajkd.2000.8266
pubmed: 10873872
Nishiura JL, Neves RF, Eloi SR, Cintra SM, Ajzen SA, Heilberg IP. Evaluation of nephrolithiasis in autosomal dominant polycystic kidney disease patients. Clin J Am Soc Nephrol. 2009;4(4):838–44.
doi: 10.2215/CJN.03100608
pubmed: 19339428
pmcid: 2666433
Chapman AB, Devuyst O, Eckardt KU, Gansevoort RT, Harris T, Horie S, Kasiske BL, Odland D, Pei Y, Perrone RD, Pirson Y, Schrier RW, Torra R, Torres VE, Watnick T, Wheeler DC, Conference Participants. Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a Kidney disease: improving global outcomes (KDIGO) controversies conference. Kidney Int. 2015;88(1):17–27.
doi: 10.1038/ki.2015.59
pubmed: 25786098
pmcid: 4913350
Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J, CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604–12.
doi: 10.7326/0003-4819-150-9-200905050-00006
pubmed: 19414839
pmcid: 2763564
Keddis MT, Rule AD. Nephrolithiasis and loss of kidney function. Curr Opin Nephrol Hypertens. 2013;22(4):390–6.
doi: 10.1097/MNH.0b013e32836214b9
pubmed: 23736840
pmcid: 4074537
Delaney VB, Adler S, Bruns FJ, Licinia M, Segel DP, Fraley DS. Autosomal dominant polycystic kidney disease: presentation, complications, and prognosis. Am J Kidney Dis. 1985;5(2):104–11.
doi: 10.1016/S0272-6386(85)80004-4
pubmed: 3970015
Curhan GC. Epidemiology of stone disease. Urol Clin North Am. 2007;34(3):287–93.
doi: 10.1016/j.ucl.2007.04.003
pubmed: 17678980
pmcid: 2693870
Borrego Utiel FJ, Herrera Contreras I, Merino García E, Camacho Reina MV, Moriana Domínguez C, Ocaña PE. Urinary citrate as a marker of renal function in patients with autosomal dominant polycystic kidney disease. Int Urol Nephrol. 2022;54(4):873–81.
doi: 10.1007/s11255-021-02953-0
pubmed: 34279821
Goodarzi MT, Forouzanfar F, Moaddab AH, Karimian M, Sabzevar NK. Comparison of 24-hour urinary citrate excretion in stone formers and healthy volunteers. Saudi J Kidney Dis Transpl. 2012;23(6):1227–31.
pubmed: 23168853
Riddle HAL, Zhang S, Qian F, Williams JC Jr, Stubbs JR, Rowe PSN, Parnell SC. Kidney stone formation in a novel murine model of polycystic kidney disease. Am J Physiol Renal Physiol. 2022;323(1):F59–68.
doi: 10.1152/ajprenal.00165.2021
pubmed: 35343849
pmcid: 9236864
Ferraz RR, Fonseca JM, Germino GG, Onuchic LF, Heilberg IP. Determination of urinary lithogenic parameters in murine models orthologous to autosomal dominant polycystic kidney disease. Urolithiasis. 2014;42(4):301–7.
doi: 10.1007/s00240-014-0664-1
pubmed: 24817661
pmcid: 5602548
Leslie SW, Bashir K. Hypocitraturia And Renal Calculi. [Updated 2023 Jan 4]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls publishing; 2023 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK564392 .